MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026PRNewsWire • 03/12/26
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease DiagnosisBusiness Wire • 03/12/26
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/12/26
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference TranscriptSeeking Alpha • 03/05/26
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder PreservationBusiness Wire • 02/27/26
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/27/26
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck CancerBusiness Wire • 02/24/26
Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/23/26
Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & DecisionsSeeking Alpha • 02/20/26
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026Business Wire • 02/17/26
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy OutcomesBusiness Wire • 02/06/26
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD TestZacks Investment Research • 02/03/26
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart TransplantationBusiness Wire • 01/28/26